XNAS · Healthcare · Medical Devices
INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The company's segments include: The Clinics Services operating segment consisting of financial information for WFI and the Atlanta Clinic and The INVOcell Device operating segment consisting of financial information relating to the manufacture and sales of the INVOcell.
The key catalyst is a new **$15M equity purchase agreement**, which buys liquidity but signals heavy dilution risk for this tiny medical-device turnaround story. Q2 was weak overall: revenue was just **$2M** and margins remained deeply negative at **-367%**, despite an EPS beat versus a very low bar.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-17 | Q2 2026 | -5.60 | 0.35 | +106.25% | $2.2M | ✅ Beat | +1.83% | -32.68% | — |
| 2026-06-22 | Q1 2026 | -10.00 | -3.38 | +66.20% | $2.0M | ✅ Beat | -1.44% | +43.17% | -25.18% |
| 2026-06-02 |
| Q4 2025 |
| -22.00 |
| -40.40 |
| -83.64% |
| $1.6M |
| ❌ Miss |
| +0.36% |
| -7.89% |
| +6.58% |
| 2025-11-17 | Q3 2025 | — | -0.77 | — | $1.8M | — | — | — | — |
| 2025-04-28 | Q4 2024 | — | -9.04 | — | $1.7M | — | -9.04% | +31.64% | -2.26% |
| 2024-11-19 | Q3 2024 | — | -5.04 | — | $1.4M | — | — | — | — |
| 2024-08-14 | Q2 2024 | — | -7.44 | — | $1.8M | — | — | — | — |
| 2024-05-15 | Q1 2024 | — | -5.04 | — | $1.6M | — | — | — | — |
Showing last 8 quarters.